The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population
- PMID: 24728189
- PMCID: PMC4119409
- DOI: 10.1093/hmg/ddu172
The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population
Abstract
The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population. The coding sequence and splice site boundaries of all six genes were amplified in germline DNA from 2240 invasive EOC cases and 1535 controls. Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and sequence data for each subject de-multiplexed prior to interpretation. GATK and Annovar were used for variant detection and annotation. After quality control 2222 cases (99.2%) and 1528 controls (99.5%) were included in the final analysis. We identified 193 EOC cases (8.7%) carrying a deleterious mutation in at least one gene compared with 10 controls (0.65%). Mutations were most frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8%) carrying a BRCA1 mutation and 94 EOC cases (4.2%) carrying a BRCA2 mutation. The combined BRCA1 and BRCA2 mutation prevalence was 11% in high-grade serous disease. Seventeen EOC cases carried a mutation in a mismatch repair gene, including 10 MSH6 mutation carriers (0.45%) and 4 MSH2 mutation carriers (0.18%). At least 1 in 10 women with high-grade serous EOC has a BRCA1 or BRCA2 mutation. The development of next generation sequencing technologies enables rapid mutation screening for multiple susceptibility genes at once, suggesting that routine clinical testing of all incidence cases should be considered.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Similar articles
-
High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.Breast Cancer Res Treat. 2018 Apr;168(3):695-702. doi: 10.1007/s10549-017-4635-4. Epub 2018 Jan 2. Breast Cancer Res Treat. 2018. PMID: 29297111
-
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.Gynecol Oncol. 2020 Feb;156(2):377-386. doi: 10.1016/j.ygyno.2019.11.019. Epub 2019 Nov 18. Gynecol Oncol. 2020. PMID: 31753525
-
Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.J Hum Genet. 2019 Apr;64(4):281-290. doi: 10.1038/s10038-019-0562-z. Epub 2019 Jan 16. J Hum Genet. 2019. PMID: 30651582
-
Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.Ann Surg Oncol. 2016 May;23(5):1729-35. doi: 10.1245/s10434-015-5026-x. Epub 2016 Jan 4. Ann Surg Oncol. 2016. PMID: 26727920
-
Epithelial ovarian cancer risk: A review of the current genetic landscape.Clin Genet. 2020 Jan;97(1):54-63. doi: 10.1111/cge.13566. Epub 2019 May 29. Clin Genet. 2020. PMID: 31099061 Free PMC article. Review.
Cited by
-
The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.Int J Cancer. 2022 Nov 1;151(9):1626-1639. doi: 10.1002/ijc.34165. Epub 2022 Jul 6. Int J Cancer. 2022. PMID: 35792468 Free PMC article.
-
A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.J Med Genet. 2015 Jul;52(7):465-75. doi: 10.1136/jmedgenet-2015-103077. Epub 2015 May 29. J Med Genet. 2015. PMID: 26025000 Free PMC article.
-
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.J Natl Cancer Inst. 2015 Aug 27;107(11):djv214. doi: 10.1093/jnci/djv214. Print 2015 Nov. J Natl Cancer Inst. 2015. PMID: 26315354 Free PMC article.
-
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells.Sci Rep. 2023 Dec 19;13(1):22659. doi: 10.1038/s41598-023-50151-y. Sci Rep. 2023. PMID: 38114660 Free PMC article.
-
NIPS, a 3D network-integrated predictor of deleterious protein SAPs, and its application in cancer prognosis.Sci Rep. 2018 Apr 16;8(1):6021. doi: 10.1038/s41598-018-24286-2. Sci Rep. 2018. PMID: 29662108 Free PMC article.
References
-
- Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 2010;127:2893–2917. - PubMed
-
- Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63:11–30. - PubMed
-
- Finch A., Evans G., Narod S.A. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond. Engl) 2012;8:543–555. - PubMed
-
- Stratton J.F., Pharoah P., Smith S.K., Easton D., Ponder B.A. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br. J. Obstet. Gynaecol. 1998;105:493–499. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous